Home > Insider Trading > Filing (0001209191-11-051055)

Filing Details

Accession Number:: 0001209191-11-051055
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2011-10-06 17:51:31
Reporting Period:: 2011-09-28

Filing Date:: 2011-10-06
Accepted Time:: 2011-10-06 17:51:31
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1135906	Zalicus Inc.	ZLCS	Pharmaceutical Preparations (2834)	043514457

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1134655	Ansbert Gadicke	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No
1134657	Luke Evnin	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No
1166285	Michael Steinmetz	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No
1221595	Iii J Nicholas Simon	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No
1249153	Dennis Henner	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No
1252522	Nicholas Galakatos	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No
1252525	Kurt Wheeler	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2011-09-28	100,000	$1.02	14,123,961	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2011-09-29	53,800	$1.02	14,070,161	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2011-09-30	23,308	$1.02	14,046,853	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2011-10-05	33,124	$1.02	14,013,729	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2011-10-06	170,000	$1.02	13,843,729	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

The shares were sold as follows: 83,242 by MPM BioVentures III-QP, L.P. ("BV III QP"), 5,597 by MPM BioVentures III, L.P. ("BV III"), 1,612 by MPM Asset Management Investors 2003 BVIII LLC ("AM 2003"), 2,514 by MPM BioVentures III Parallel Fund, L.P. ("BV Parallel") and 7,035 by MPM BioVentures III GmbH & Co. Beteiligungs KG ("BV KG").
Represents weighted average sales price. The shares were sold at prices ranging from $1.02 to $1.03. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
The shares are held as follows: 11,696,671 by BV III QP, 785,287 by BV III, 226,164 by AM 2003, 352,257 by BV Parallel, 987,267 by BV KG and 76,315 by MPM Asset Management LLC ("MPM AM"). MPM BioVentures III GP, L.P. ("MPM III GP") and MPM BioVentures III LLC ("MPM III LLC") are the direct and indirect general partners of BV III QP, BV III and BV Parallel and BV KG. Luke Evnin, Ansbert Gadicke, Nicholas Galakatos, Dennis Henner, Nicholas Simon III, Michael Steinmetz and Kurt Wheeler are the members of MPM III LLC and AM 2003. Luke Evnin and Ansbert Gadicke are members of MPM AM. Each reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his or its respective pecuniary interest therein.
The shares were sold as follows: 42,782 by BV III QP, 2,876 by BV III, 828 by AM 2003, 1,292 by BV Parallel, 3,615 by BV KG and 2,407 by MPM AM.
The shares are held as follows: 11,653,889 by BV III QP, 782,411 by BV III, 225,336 by AM 2003, 350,965 by BV Parallel, 983,652 by BV KG and 73,908 by MPM AM. Each reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his or its respective pecuniary interest therein.
The shares were sold as follows: 19,300 by BV III QP, 1,298 by BV III, 374 by AM 2003, 583 by BV Parallel, 1,631 by BV KG and 122 by MPM AM.
The shares are held as follows: 11,634,589 by BV III QP, 781,113 by BV III, 224,962 by AM 2003, 350,382 by BV Parallel, 982,021 by BV KG and 73,786 by MPM AM. Each reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his or its respective pecuniary interest therein.
The shares were sold as follows: 27,430 by BV III QP, 1,844 by BV III, 531 by AM 2003, 828 by BV Parallel, 2,318 by BV KG and 173 by MPM AM.
The shares are held as follows: 11,607,159 by BV III QP, 779,269 by BV III, 224,431 by AM 2003, 349,554 by BV Parallel, 979,703 by BV KG and 73,613 by MPM AM. Each reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his or its respective pecuniary interest therein.
The shares were sold as follows: 140,773 by BV III QP, 9,465 by BV III, 2,726 by AM 2003, 4,252 by BV Parallel, 11,897 by BV KG and 887 by MPM AM.
Represents weighted average sales price. The shares were sold at prices ranging from $1.02 to $1.03. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
The shares are held as follows: 11,466,386 by BV III QP, 769,804 by BV III, 221,705 by AM 2003, 345,302 by BV Parallel, 967,806 by BV KG and 72,726 by MPM AM. Each reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his or its respective pecuniary interest therein.